# reload+after+2024-01-23 14:44:03.837853
address1§1901 West 47th Place
city§Kansas City
state§KS
zip§66205
country§United States
phone§913 942 2300
website§https://www.cingulate.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
fullTimeEmployees§15
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Shane J. Schaffer Pharm.D., PharmD', 'age': 48, 'title': 'CEO, Principal Financial Officer & Chairman of the Board', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 504688, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Laurie A. Myers M.B.A., Ph.D.', 'age': 66, 'title': 'Executive VP & COO', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 425000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Raul R. Silva M.D.', 'age': 65, 'title': 'Executive VP & Chief Science Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Thomas  Dalton', 'title': 'Head of Investor & Public Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Matthew N. Brams M.D.', 'age': 59, 'title': 'Executive VP & Chief Medical Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Jennifer L. Callahan', 'title': 'Corporate Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§-0.538
currency§USD
dateShortInterest§1702598400
forwardEps§-11.55
exchange§NCM
quoteType§EQUITY
shortName§Cingulate Inc.
longName§Cingulate Inc.
firstTradeDateEpochUtc§1638973800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§bf898f9d-c1c1-3f31-9c96-a5b2c0f73dcd
gmtOffSetMilliseconds§-18000000
targetHighPrice§70.0
targetLowPrice§35.0
targetMeanPrice§52.5
targetMedianPrice§52.5
recommendationMean§2.5
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§0.354
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
